Bill Kerr of Avalon Heath Solutions says incorporating Z codes into CPT codes for lab and genetic testing would add needed specificity, reduce waste and possibly head off fraud.
|Videos|March 17, 2022
- MHE March 2022
- Volume 32
- Issue 3
Aaron Glatt of Mount Sinai Addresses the Major Concern of Obesity on COVID-19
Author(s)Briana Contreras
Aaron Glatt, MD, Chairman of the Department of Medicine and Chief of Infectious Diseases/Hospital Epidemiologist at Mount Sinai South Nassau and Clinical Professor of Medicine at the Icahn School of Medicine at Mount Sinai, addressed to MHE the degree obesity is a risk factor at for severe COVID-19 and what those reasons are for obesity increasing the risk. This video is in correlation to Managed Healthcare Executive's March Issue cover story highlighting the dangerous pairing of COVID-19 and Obesity.
Advertisement
Articles in this issue
over 4 years ago
The Cost Burden of Alzheimer'sover 4 years ago
Frequent and Feared. But Can Dementia Be Avoided?over 4 years ago
Cancer Mortality is Decreasing in the U.S.over 4 years ago
New TEFCA Framework Brings Some Clarity to Interoperability Pushover 4 years ago
Fourth Shot is Recommended for the Immunocompromisedover 4 years ago
New COVID-19 Vaccines are in Late-stage Trialsover 4 years ago
Insurers and COVID-19 TestsAdvertisement
Related to this article
States have to turn that information into medical frailty determinations that are clinically credible, consistent, and workable across large Medicaid populations.
A meta-analysis found steatotic liver disease in 75% of patients with sleep-disordered breathing and that CPAP lowered liver enzymes but not liver fat.
Some predicted that drugmakers might boost launch prices to make up for Medicare drug negotiations shrinking profits. Harvard researchers find no evidence of that happening so far.
State PBM reform accelerates through 2026, with Theresa Carnegie of Mintz unpacking new laws, rebate pass-through, spread pricing bans, and compliance risks.
Only 19.1% of commercially insured patients with first-episode psychosis were adherent to antipsychotics in the year after starting treatment.
Prioritizing referral completion as much as referral generation will equip organizations to measure results and improve health outcomes.
Daiichi Sankyo and Merck pulled their bid for accelerated approval of I-DXd in small cell lung cancer after the FDA found phase 2 data fell short.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Tariffs on patented drugs now apply to all branded drugmakers
2
A head-to-head phase 3b comparison of bimekizumab with risankizumab in active psoriatic arthritis: Written recap
3
FAQ: State PBM reform in 2026—What's new since spring
4
IRA drug price negotiation has not increased launch prices, study finds
5